Xin-xu Li1, Tong-Chong Zhou, Jian Zhao. 1. Department of Surgery, Sanshui District Hospital of Traditional Chinese Medicine, Foshan 5281001, China. lxx_xnyy@163.com
Abstract
OBJECTIVE: To compare the therapeutic effects of single- and combined-modality therapy on bone metastasis of non-small-cell lung cancer. METHODS: Seventy patients with bone metastasis of non-small-cell lung cancer were treated with one of the therapeutic modalities of radiotherapy, radioisotope, chemotherapy or medication with Bonefos respectively, while another 71 cases received combined-modality therapy through different combinations of the already listed modalities. RESULTS: The single modality of radiotherapy, radioisotope, chemotherapy and Bonefos had similar efficacy in treating the bone metastasis cases, which were 55.0%, 56.2%, 42.1% and 53.3% respectively, with a total efficacy rate of 51.4%. Combined-modality therapy proved to be much superior in terms of the total efficacy rate (76.0%, P <0.05), but the blood and the gastrointestinal toxicity was not significantly reduced as compared with that in single-modality group (P >0.05). CONCLUSION: The combined- modality therapy is more effective for treating bone metastasis of non-small-cell lung cancer than single-modality therapy.
OBJECTIVE: To compare the therapeutic effects of single- and combined-modality therapy on bone metastasis of non-small-cell lung cancer. METHODS: Seventy patients with bone metastasis of non-small-cell lung cancer were treated with one of the therapeutic modalities of radiotherapy, radioisotope, chemotherapy or medication with Bonefos respectively, while another 71 cases received combined-modality therapy through different combinations of the already listed modalities. RESULTS: The single modality of radiotherapy, radioisotope, chemotherapy and Bonefos had similar efficacy in treating the bone metastasis cases, which were 55.0%, 56.2%, 42.1% and 53.3% respectively, with a total efficacy rate of 51.4%. Combined-modality therapy proved to be much superior in terms of the total efficacy rate (76.0%, P <0.05), but the blood and the gastrointestinal toxicity was not significantly reduced as compared with that in single-modality group (P >0.05). CONCLUSION: The combined- modality therapy is more effective for treating bone metastasis of non-small-cell lung cancer than single-modality therapy.
Authors: Maria A Lopez-Olivo; Nimit A Shah; Greg Pratt; Jan M Risser; Elaine Symanski; Maria E Suarez-Almazor Journal: Support Care Cancer Date: 2012-09-07 Impact factor: 3.603